The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
Lee, Rebecca J
Lorigan, Paul C
Dean, Emma J
Krebs, Matthew G
AffiliationMolecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, SK10 4TG,
MetadataShow full item record
AbstractBackground: KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas (PDAC), ∼35% of colorectal cancers (CRC) and ∼20% of non-small-cell lung cancers (NSCLC). There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the complexity of downstream signaling and feedback mechanisms mean that targeting individual pathway components is ineffective. Design: The protein kinases RAF and SRC are validated therapeutic targets in KRAS-mutant PDAC, CRC and NSCLC and we show that both must be inhibited to block growth of these cancers. We describe CCT3833, a new drug that inhibits both RAF and SRC which may be effective in KRAS-mutant cancers. Results: We show that CCT3833 inhibits RAF and SRC in KRAS-mutant tumors in vitro and in vivo, and that it inhibits tumor growth at well-tolerated doses in mice. CCT3833 has been evaluated in a Phase I clinical trial (NCT02437227) and we report here that it significantly prolongs progression-free survival of a patient with a G12VKRAS spindle cell sarcoma who did not respond to a multi kinase inhibitor and therefore had limited treatment options. Conclusions: New drug CCT3833 elicits significant pre-clinical therapeutic efficacy in KRAS-mutant colorectal, lung and pancreatic tumor xenografts, demonstrating a treatment option for several areas of unmet clinical need. Based on these pre-clinical data, and the Phase I clinical unconfirmed response in a patient with KRAS-mutant spindle cell CCT3833 requires further evaluation in patients with other KRAS-mutant cancers.
CitationSaturno G, Lopes F, Niculescu-Duvaz I, Niculescu-Duvaz D, Zambon A, Davies L, et al. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Ann Oncol. 2020.
JournalAnnals of Oncology
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
- Authors: Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R
- Issue date: 2018 Jul
- An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
- Authors: Wang H, Lv Q, Xu Y, Cai Z, Zheng J, Cheng X, Dai Y, Jänne PA, Ambrogio C, Köhler J
- Issue date: 2019 Nov
- Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
- Authors: Molina-Arcas M, Moore C, Rana S, van Maldegem F, Mugarza E, Romero-Clavijo P, Herbert E, Horswell S, Li LS, Janes MR, Hancock DC, Downward J
- Issue date: 2019 Sep 18
- LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
- Authors: Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF
- Issue date: 2017 Feb 7
- Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
- Authors: Umelo IA, De Wever O, Kronenberger P, Van Deun J, Noor A, Singh K, Teugels E, Chen G, Bracke M, De Grève J
- Issue date: 2015 Aug 21